Amplitude Surgical - First Quarter 2024-25: Consolidated Sales of EUR21.8m, +7.5% at Constant Exchange Rates
--
Consolidated sales of EUR21.8m, up +7.5% at constant exchange rates
--
Sales up 4.5% in France
--
Strong international growth thanks to subsidiaries, with sales up
+20.1% at constant exchange rates
VALENCE, France--(BUSINESS WIRE)--November 21, 2024--
Regulatory News:
Amplitude Surgical (ISIN: FR0012789667, Mnemo: AMPLI, PEA-PME eligible), the French market leader in surgical technologies for lower limb orthopedics, announces its consolidated sales for the first quarter of the 2024-25 financial year.
Olivier Jallabert, Chief Executive Officer of Amplitude Surgical, comments: "In the first quarter of the 2024-25 financial year, Amplitude Surgical continued its good momentum as the previous year, posting growth of +7.5% at constant exchange rates compared with the first quarter of 2023-24. Sales growth was driven in particular by a +20.1% increase at constant exchange rates in sales by international subsidiaries, and by a continued good level of business in France, up +4.5%."
Q1 sales for fiscal year 2024-2025
Change at
Change at current constant
Q1 2024-25 Sales 30/09/2024 30/09/2023 exchange rates exchange rates
----------------- ---------- ---------- ----------------- ----------------
In KEUR - IFRS
----------------- ---------- ---------- ----------------- ----------------
Knee and hip
activities 21,753 20,507 6.1% 7.5%
----------------- ---------- ---------- ----------------- ----------------
Total 21,753 20,507 6.1% 7.5%
----------------- ---------- ---------- ----------------- ----------------
In the first quarter (July-September 2024) of the 2024-25 financial year, Amplitude Surgical sales came to EUR21.8 million, up 6.1% and 7.5% at constant exchange rates.
Sales in France rose by 4.5%, while international distributors were down -4.1%, and the Group's international subsidiaries recorded an increase of 14.1% at current exchange rates and 20.1% at constant exchange rates.
Amplitude Surgical's direct sales (French market and international subsidiaries), which account for almost 93% of total Group sales, rose by +8.5% at constant exchange rates.
In France, the Group continued to grow as in the previous year. France accounted for around 67% of Group sales in the first quarter of the 2024-25 financial year.
International subsidiaries reported strong growth at constant exchange rates in Belgium, Australia and Brazil, while sales in Switzerland and Germany were down.
Next press release:
Half-year sales 1(st) 2024-25: Thursday, February 20, 2025, after market close.
About Amplitude Surgical
Founded in 1997 in Valence, France, Amplitude Surgical is a leading French player in the global market for surgical technologies for lower limb orthopedics. Amplitude Surgical develops and markets high-end products for orthopedic surgery, covering the main pathologies affecting the hip and knee. Working in close collaboration with surgeons, Amplitude Surgical develops numerous high value-added innovations to best meet the needs of patients, surgeons and care facilities. A leading player in France, Amplitude Surgical is expanding internationally through its subsidiaries and a network of agents and exclusive distributors in over 30 countries. As of June 30, 2024, Amplitude Surgical employed 428 people and generated sales of nearly 106.0 million euros.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241121339023/en/
CONTACT: Amplitude Surgical
Dimitri Borchtch
Chief Financial Officer
finances@amplitude-surgical.com
04 75 41 87 41
NewCap
Investor Relations
Thomas Grojean
amplitude@newcap.eu
01 44 71 94 94
NewCap
Media Relations
Nicolas Merigeau
amplitude@newcap.eu
01 44 71 94 98
(END) Dow Jones Newswires
November 21, 2024 12:00 ET (17:00 GMT)
Comments